Market closedNon-fractional
ESSA Pharma/EPIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ESSA Pharma
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Ticker
EPIX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Vancouver, Canada
Employees
50
Website
www.essapharma.com
ESSA Pharma Metrics
BasicAdvanced
$223M
Market cap
-
P/E ratio
-$0.63
EPS
1.82
Beta
-
Dividend rate
Price and volume
Market cap
$223M
Beta
1.82
Financial strength
Current ratio
32.891
Quick ratio
32.605
Long term debt to equity
0.19
Total debt to equity
0.265
Interest coverage (TTM)
-12,895.51%
Management effectiveness
Return on assets (TTM)
-14.40%
Return on equity (TTM)
-19.14%
Valuation
Price to book
1.68
Price to tangible book (TTM)
1.68
Price to free cash flow (TTM)
-9.634
Growth
Earnings per share change (TTM)
-4.84%
3-year earnings per share growth
-13.84%
What the Analysts think about ESSA Pharma
Analyst Ratings
Majority rating from 4 analysts.
ESSA Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8.9M
50.85%
Profit margin
0.00%
NaN%
ESSA Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.17
-$0.12
-$0.14
-$0.20
-
Expected
-$0.20
-$0.21
-$0.17
-$0.19
-$0.25
Surprise
-12.82%
-42.86%
-18.84%
6.38%
-
ESSA Pharma News
AllArticlesVideos
ESSA Pharma to Present at the Jefferies Global Healthcare Conference
PRNewsWire·1 month ago
ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer
Seeking Alpha·1 month ago
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
PRNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ESSA Pharma stock?
ESSA Pharma (EPIX) has a market cap of $223M as of July 06, 2024.
What is the P/E ratio for ESSA Pharma stock?
The price to earnings (P/E) ratio for ESSA Pharma (EPIX) stock is 0 as of July 06, 2024.
Does ESSA Pharma stock pay dividends?
No, ESSA Pharma (EPIX) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next ESSA Pharma dividend payment date?
ESSA Pharma (EPIX) stock does not pay dividends to its shareholders.
What is the beta indicator for ESSA Pharma?
ESSA Pharma (EPIX) has a beta rating of 1.82. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell ESSA Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.